Cerebral Infarction (Brain Infarction) - Pipeline Review, H1 2014 - ABC6 - Providence, RI and New Bedford, MA News, Weather

Cerebral Infarction (Brain Infarction) - Pipeline Review, H1 2014

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE ReportBuyer

LONDON, July 2, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

Cerebral Infarction (Brain Infarction) - Pipeline Review, H1 2014

http://www.reportbuyer.com/pharma_healthcare/treatments/cerebral_infarction_brain_infarction_pipeline_review_h1_2013.html

Cerebral Infarction (Brain Infarction) - Pipeline Review, H1 2014

Summary

Global Markets Direct's, 'Cerebral Infarction (Brain Infarction) - Pipeline Review, H1 2014', provides an overview of the Cerebral Infarction (Brain Infarction)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Cerebral Infarction (Brain Infarction), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cerebral Infarction (Brain Infarction) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Cerebral Infarction (Brain Infarction)- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Cerebral Infarction (Brain Infarction) and enlists all their major and minor projects- The report summarizes all the dormant and discontinued pipeline projects - A review of the Cerebral Infarction (Brain Infarction) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages- A detailed assessment of monotherapy and combination therapy pipeline projects- Coverage of the Cerebral Infarction (Brain Infarction) pipeline on the basis of target, MoA, route of administration and molecule type- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage- Develop strategic initiatives by understanding the focus areas of leading companies- Identify and understand important and diverse types of therapeutics under development for Cerebral Infarction (Brain Infarction)- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline- Devise corrective measures for pipeline projects by understanding Cerebral Infarction (Brain Infarction) pipeline depth and focus of Indication therapeutics- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipelineTable of Contents

Introduction 5

Global Markets Direct Report Coverage 5

Cerebral Infarction (Brain Infarction) Overview 6

Therapeutics Development 7

Pipeline Products for Cerebral Infarction (Brain Infarction) - Overview 7

Pipeline Products for Cerebral Infarction (Brain Infarction) - Comparative Analysis 8

Cerebral Infarction (Brain Infarction) - Therapeutics under Development by Companies 9

Cerebral Infarction (Brain Infarction) - Therapeutics under Investigation by Universities/Institutes 10

Cerebral Infarction (Brain Infarction) - Pipeline Products Glance 11

Clinical Stage Products 11

Early Stage Products 12

Cerebral Infarction (Brain Infarction) - Products under Development by Companies 13

Cerebral Infarction (Brain Infarction) - Products under Investigation by Universities/Institutes 14

Cerebral Infarction (Brain Infarction) - Companies Involved in Therapeutics Development 15

Johnson & Johnson 15

CIMAB S.A. 16

Shin Nippon Biomedical Laboratories, Ltd. 17

Aprogen, Inc. 18

Cerebral Infarction (Brain Infarction) - Therapeutics Assessment 19

Assessment by Monotherapy Products 19

Assessment by Target 20

Assessment by Mechanism of Action 22

Assessment by Route of Administration 24

Assessment by Molecule Type 26

Drug Profiles 28

Autologous Bone Marrow Derived Mesenchymal Stem Cells - Drug Profile 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

epoetin alfa - Drug Profile 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

CNTO-0007 - Drug Profile 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

AP-102 - Drug Profile 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

Drug For Cerebral Infarction - Drug Profile 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

Anti-HMGB1 Monoclonal Antibody - Drug Profile 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

Cerebral Infarction (Brain Infarction) - Dormant Projects 34

Cerebral Infarction (Brain Infarction) - Discontinued Products 35

Cerebral Infarction (Brain Infarction) - Product Development Milestones 36

Featured News & Press Releases 36

May 08, 2014: FDA approves Zontivity to reduce the risk of heart attacks and stroke in high-risk patients 36

Sep 28, 2012: Mitsubishi Tanabe Pharma And Kyowa Hakko File Joint Application For Time-window Extension Of Thrombolytic Agents Grtpa And Activacin 36

Sep 28, 2012: Two Pharma Companies File Joint Application With Ministry Of Health, Labour And Welfare For Time-window Extension Of Thrombolytic Agents 37

Apr 27, 2010: Asahi Kasei Pharma Announces Preliminary Results From Phase III Clinical Study Of AT-877 For Acute Cerebral Infarction 38

Appendix 39

Methodology 39

Coverage 39

Secondary Research 39

Primary Research 39

Expert Panel Validation 39

Contact Us 40

Disclaimer 40

List of Tables

Number of Products under Development for Cerebral Infarction (Brain Infarction), H1 2014 7

Number of Products under Development for Cerebral Infarction (Brain Infarction) - Comparative Analysis, H1 2014 8

Number of Products under Development by Companies, H1 2014 9

Number of Products under Investigation by Universities/Institutes, H1 2014 10

Comparative Analysis by Clinical Stage Development, H1 2014 11

Comparative Analysis by Early Stage Development, H1 2014 12

Products under Development by Companies, H1 2014 13

Products under Investigation by Universities/Institutes, H1 2014 14

Cerebral Infarction (Brain Infarction) - Pipeline by Johnson & Johnson, H1 2014 15

Cerebral Infarction (Brain Infarction) - Pipeline by CIMAB S.A., H1 2014 16

Cerebral Infarction (Brain Infarction) - Pipeline by Shin Nippon Biomedical Laboratories, Ltd., H1 2014 17

Cerebral Infarction (Brain Infarction) - Pipeline by Aprogen, Inc., H1 2014 18

Assessment by Monotherapy Products, H1 2014 19

Number of Products by Stage and Target, H1 2014 21

Number of Products by Stage and Mechanism of Action, H1 2014 23

Number of Products by Stage and Route of Administration, H1 2014 25

Number of Products by Stage and Molecule Type, H1 2014 27

Cerebral Infarction (Brain Infarction) - Dormant Projects, H1 2014 34

Cerebral Infarction (Brain Infarction) - Discontinued Products, H1 2014 35

List of Figures

Number of Products under Development for Cerebral Infarction (Brain Infarction), H1 2014 7Number of Products under Development for Cerebral Infarction (Brain Infarction) - Comparative Analysis, H1 2014 8Number of Products under Development by Companies, H1 2014 9Comparative Analysis by Clinical Stage Development, H1 2014 11Comparative Analysis by Early Stage Products, H1 2014 12Assessment by Monotherapy Products, H1 2014 19Number of Products by Top 10 Target, H1 2014 20Number of Products by Stage and Top 10 Target, H1 2014 21Number of Products by Top 10 Mechanism of Action, H1 2014 22Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 23Number of Products by Top 10 Route of Administration, H1 2014 24Number of Products by Stage and Top 10 Route of Administration, H1 2014 25Number of Products by Top 10 Molecule Type, H1 2014 26Number of Products by Stage and Top 10 Molecule Type, H1 2014 27

Companies Mentioned

Johnson & Johnson

CIMAB S.A.

Shin Nippon Biomedical Laboratories, Ltd.

Aprogen, Inc.

Read the full report:

Cerebral Infarction (Brain Infarction) - Pipeline Review, H1 2014

http://www.reportbuyer.com/pharma_healthcare/treatments/cerebral_infarction_brain_infarction_pipeline_review_h1_2013.html

For more information: Sarah Smith Research Advisor at Reportbuyer.com Email: query@reportbuyer.com Tel: +44 208 816 85 48 Website: www.reportbuyer.com

 

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow

10 Orms Street Providence, R.I. 02904
401-453-8000

All content © Copyright 2000 - 2014 WorldNow and WLNE.
All Rights Reserved.

For more information on this site, please read our Privacy Policy and Terms of Service.